Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puretech Health Plc ADR (NQ: PRTC )

17.90 +0.82 (+4.80%)
Streaming Delayed Price Updated: 11:17 AM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,947
Open 17.60
Bid (Size) 17.10 (1)
Ask (Size) 18.50 (5)
Prev. Close 17.08
Today's Range 17.57 - 17.90
52wk Range 17.08 - 38.51
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
From PureTech Health plc
Via Business Wire

Performance

YTD
-39.29%
-39.29%
1 Month
-10.50%
-10.50%
3 Month
-28.97%
-28.97%
6 Month
-36.07%
-36.07%
1 Year
-45.76%
-45.76%

More News

Read More
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
From PureTech Health plc
Via Business Wire
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
From PureTech Health plc
Via Business Wire
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
From PureTech Health plc
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
From PureTech Health plc
Via Business Wire
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
From PureTech Health plc
Via Business Wire
PureTech Health plc – Half-Year Report
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Half-Yearly Results
From PureTech Health plc
Via Business Wire
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
From PureTech Health plc
Via Business Wire
Marijuana Stock Movers For August 2, 2023
Via Benzinga
This Emerging Market Could Be the Next Big Thing in Biotech
Via The Motley Fool
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
From PureTech Health plc
Via Business Wire
Results of PureTech's Annual General Meeting
From PureTech Health plc
Via Business Wire
PureTech to Present at the Jefferies Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
From PureTech Health plc
Via Business Wire
PureTech Health FY22 Revenue Declines 10.2% YoY, Here Are The Details
Via Benzinga
PureTech Announces Annual Results for Year Ended December 31, 2022
From PureTech Health plc
Via Business Wire
Earnings Scheduled For April 28, 2023
Via Benzinga
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
From PureTech Health plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.